Clinical trials: Head and Neck Squamous Cell Carcinomas
Esophageal Cancer
Combination Chemotherapy, Radiation Therapy and Surgery in Treating Patients With Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003087
- Testing
- cisplatin, paclitaxel, surgical procedure
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Oropharyngeal Squamous Cell Carcinoma, Human Papillomavirus Infection
Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer
The purpose of this research study is to determine if saliva and oral swab samples can be used to detect human papillomavirus in patients with cancer.
- Trial name
- NCT06362421
- Testing
- Pre-Radiation Dental Evaluation/Sample Collection, Pre-Study Visit, Oral Medicine Consultation Visit/Sample Collection
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors.
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Malignant Mesothelioma, Advanced
- Trial name
- NCT03212404
- Testing
- CK-301 (cosibelimab)
- Where
- 48 sites in Australia, France and 7 more
- Volunteers
- 272 people
- Sponsor
- Checkpoint Therapeutics, Inc.
Esophageal Squamous Cell Carcinoma, Chemotherapy Effect
Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC
This study is a phase III, multicenter, prospective randomized controlled clinical study comparing the efficacy of non-surgical esophageal squamous cell carcinoma with radical chemoradiotherapy and radical chemoradiotherapy…
- Conditions
- Esophageal Squamous Cell Carcinoma, Chemotherapy Effect, Side Effect of Drug
- Trial name
- NCT05775419
- Testing
- Consolidation chemotherapy (4 courses), Concurrent chemotherapy (2 courses)
- Where
- China
- Volunteers
- 1,216 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
The purpose of this first in human (FIH) trial was to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in…
- Conditions
- Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC
- Trial name
- NCT03114319
- Testing
- TNO155, TNO155 in combination with EGF816 (nazartinib)
- Where
- 18 sites in United States, Canada and 7 more
- Volunteers
- 227 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
The purpose of this study is to assess the safety and antitumor activity of INCB001158 plus epacadostat, with or without pembrolizumab, in participants with advanced or metastatic solid tumors.
- Trial name
- NCT03361228
- Testing
- INCB001158, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incyte Corporation
Head and Neck Cancer, Oral Cavity Cancer
Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
The purpose of this study is to evaluate if the addition of valproic acid to standard platinum-based chemoradiation as definitive treatment of locally advanced Head and Neck squamous cell carcinoma can improve treatment outcomes…
- Conditions
- Head and Neck Cancer, Oral Cavity Cancer, Oropharyngeal Cancer
- Trial name
- NCT01695122
- Testing
- Valproic Acid
- Where
- Brazil
- Volunteers
- 14 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Participants with recurrent or metastatic (R/M) squamous cell cancer of the head and neck (HNSCC) will be randomly assigned to receive pembrolizumab monotherapy [pembro mono], pembrolizumab plus chemotherapy with a platinum-based…
- Trial name
- NCT02358031
- Testing
- Pembrolizumab, Cisplatin, Carboplatin
- Volunteers
- 882 people
- Sponsor
- Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma
Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma
The goal of this observational study is to learn about the Effects of neoadjuvant therapy with carboplatin, paclitaxel combined with anti-PD-1 drugs on pain, anxiety and depression in patients with operable head and neck squamous…
- Trial name
- NCT06575322
- Testing
- Carboplatin（ neoadjuvant）, Paclitaxel （neoadjuvant）, Anti-PD-1 Drugs
- Where
- China
- Volunteers
- 302 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Solid Tumours, Sarcoma
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which…
- Conditions
- Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer
- Trial name
- INVOKE (NCT06789172)
- Testing
- OKN4395, Pembrolizumab, Fasting
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- Epkin
Head and Neck Squamous Cell Carcinoma
AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy
Currently, there is a lack of high-quality clinical evidence for subsequent treatment options for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) after first-line treatment, especially for subsequent treatment…
- Trial name
- NCT06494995
- Testing
- Cadonilimab, Low-dose radiotherapy, SBRT
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Fudan University
Esophagus Cancer, Radiotherapy
A Clinical Study of Non-curative Resection Plus Radiotherapy After Endoscopic ESD for Superficial Esophageal Squamous Cell Carcinoma
The goal of observational study is to learn about the outcomes of the participants. The main questions it aims to answer are: 1.
- Conditions
- Esophagus Cancer, Radiotherapy, Endoscopic Mucosal Resection
- Trial name
- NCT06160557
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xiaomeng Zheng
Esophageal Squamous Cell Carcinoma
Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer
This study is an open-label, biomarker-integrated umbrella trial designed to evaluate the clinical efficacy of molecular subtype- and genomic biomarker-guided precision therapies in patients with advanced esophageal cancer…
- Trial name
- ESCC-PT (NCT07653451)
- Testing
- Afatinib + Toripalimab, Dalpiciclib + Pyrotinib, Camrelizumab + Apatinib
- Volunteers
- 90 people
- Sponsor
- Peking University Cancer Hospital & Institute
Squamous Cell Carcinoma of the Larynx
HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer
single-modality phase I dose escalation toxicity study for first-line curative treatment of head and neck squamous cell carcinoma.
- Trial name
- HYDRA (NCT02464137)
- Testing
- radiation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Texas Southwestern Medical Center
Esophageal Squamous Cell Carcinoma (ESCC)
O-GlcNAcylation Induced HMGB1 Signalling
This study investigates how HMGB1 compartmentalisation and O-GlcNAcylation regulate inflammatory signalling, autophagy, and immune escape in cancer.
- Trial name
- NCT07702253
- Testing
- specimen collection
- Where
- Hong Kong
- Volunteers
- 120 people
- Sponsor
- Chinese University of Hong Kong
Head and Neck Cancer
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as E7389, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00337129
- Testing
- eribulin mesylate
- Where
- 139 sites in United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Neck Dissection
Use of the Harmonic Scalpel in Neck Dissection
Neck dissection is the main technique used by head and neck surgeons to treat known or suspected metastatic cancer to the neck. The traditional radical neck dissection was effective at treating metastatic cancer to the neck…
- Trial name
- NCT00875953
- Testing
- standard neck dissection, Harmonic Scalpel Dissection
- Where
- Canada
- Volunteers
- 34 people
- Sponsor
- University of Calgary
Esophageal Squamous Cell Carcinoma (ESCC)
A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of neoadjuvant toripalimab combined with chemotherapy and low-dose radiotherapy in patients with esophageal squamous cell carcinoma who are insensitive to…
- Trial name
- NCT07272291
- Testing
- Toripalimab
- Volunteers
- 48 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Squamous Cell Carcinoma of the Head and Neck
Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma
Study of the combination of acalabrutinib (ACP-196) and pembrolizumab in subjects with advanced head and neck squamous cell carcinoma.
- Trial name
- KEYNOTE147 (NCT02454179)
- Testing
- pembrolizumab, Acalabrutinib
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Acerta Pharma BV
Oropharyngeal Squamous Cell Carcinoma
Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.
This study is a phase II, multicenter, open-label study that has been designed to evaluate the efficacy and the safety of definitive Radiotherapy (RT) (70 Gy) delivered in combination with the anti-PD-L1 Durvalumab immunotherapy…
- Trial name
- CITHARE (NCT03623646)
- Testing
- Chemoradiotherapy arm, Immunotherapy + Radiotherapy arm
- Where
- 2 sites in France
- Volunteers
- 11 people
- Sponsor
- Institut Claudius Regaud
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.